#Israel #Rehovot #AgPlenus #Evogene Ltd #ChemPass AI

Evogene Ltd. Reports First Quarter 2026 Financial Results

Overview

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), an innovative player in computational chemistry focusing on generative AI for small molecules, has recently disclosed its financial performance for the first quarter ending March 31, 2026. This report underscores Evogene's ongoing commitment to advancing its technology and product pipeline in both the pharmaceutical and agricultural sectors.

Financial Highlights

According to Ofer Haviv, President and CEO of Evogene, the company is now concentrating on execution and the growth of its small-molecule discovery technology, ChemPass AI™. The financial results for Q1 2026 reflect a revenue decline to approximately $0.3 million, down from $2.3 million in the previous year, largely due to reduced seed sales from the Casterra subsidiary.

Operating losses reached around $3.2 million, an increase compared to $3.0 million from the year prior. However, Evogene has managed to maintain a consolidated cash position of approximately $13.1 million, despite spending about $2.8 million during the quarter. Amidst these challenges, the company announced three new collaborations aimed at harnessing innovative solutions for inflammatory diseases and oncology, demonstrating its strategic expansion in the biotech arena.

ChemPass AI™ and Collaborations

ChemPass AI™ continues to stand out, offering an ability to produce innovative molecules while optimizing key parameters from the design's inception. Evogene's collaborations with tech firms, particularly a notable partnership with Google Cloud, are aimed at revolutionizing dataset generation through advanced AI integration. This collaboration is set to bolster the efficacy of small-molecule discovery initiatives significantly.

Advancements in Pharma and Agriculture

In the pharmaceutical sector, Evogene's efforts have led to partnerships with several biotech companies and academic institutions, strengthening its development of therapies for diseases like multiple sclerosis and other inflammatory conditions. These collaborations, including those with Systasy Biosciences and Queensland University of Technology, showcase Evogene's ambition to spearhead therapeutic innovations.

On the agricultural front, AgPlenus, Evogene’s subsidiary, is making strides with novel herbicide programs, in collaboration with Corteva. Although a partnership with Bayer to develop herbicides was terminated due to unmet product criteria, this shift allows AgPlenus to focus on more promising avenues. Evogene's commitment to optimizing AI-driven design in agriculture remains robust, as seen in their active lead optimization efforts in fungicides as well.

Future Outlook

Looking ahead, Evogene aims to continue making significant progress across its core areas, including technology expansion, which is vital for achieving key milestones in pharma and ag-chemicals. The company emphasizes deeper collaboration with industry leaders to enhance its ChemPass AI™ capabilities and accelerate product pipeline growth.

In conclusion, despite facing financial hurdles, Evogene's strategic initiatives reflect a strong commitment to innovation and collaboration in both pharmaceutical and agricultural scientific fields. The company is poised to enhance its position as a leader in computational chemistry and generative AI, harnessing advanced technology to deliver groundbreaking products.

Conclusion

Evogene remains focused on leveraging its proprietary technology and expanding its partnerships as it navigates the evolving landscape of pharmaceuticals and agriculture. The Company looks forward to achieving its growth trajectory through sustained innovation and commitment to advancing human health and agricultural productivity.